Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases

Journal of Allergy and Clinical Immunology

Volumn 100, Issue 2, 1997, Pages 151-157

  Ballow, Mark ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b CHILDREN S HOSPITAL OF BUFFALO   (United States)

Author keywords

Autoimmune disease; Complement; Cytokines; Fc receptors; Immune modulation; Immune therapy; Intravenous immune serum globulin (IVIG); globulin

Indexed keywords

IMMUNOGLOBULIN;

ALLERGIC ENCEPHALOMYELITIS; AUTOIMMUNITY; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INFLAMMATORY DISEASE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRIORITY JOURNAL; REVIEW;

EID: 0030807625     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(97)70217-3     Document Type: Review

References (70)

1. Imbach P, d'Apuzzo V, Baumgartner C. High dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981;1:1228-30.
2. Bussel J, Pahwa S, Porges A, Changes in the vitro antibody synthesis in ITP treated with intravenous gamma globulin are closely linked to long-term outcome. J Clin Immunol 1986;6:50-6.
3. Bussel JB. Modulation of Fc receptor clearance and antiplatelet antibodies as a consequence of intravenous immune globulin infusion in patients with immune thrombocytopenic purpura. J Allergy Clin Immunol 1989;84:566-78.
4. Fehr J, Hofmann V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gammaglobulin. N Engl J Med 1982;306:1254-8.
5. Debré M, Bonnet M-C, Fridman W-H, Carosella E, Phillippe N, Reinert P, Vilmer E, et al. Infusion of Fcγ fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 1993;342:945-9.
6. Mannhalter JW, Eibl MM. Down regulation of Fc receptors by IVIgG. Int Rev Immunol 1989;5:173-9.
7. Mannhalter J, Ahmad R, Wolf HM, Eibl MM. Effect of polymeric IgG on human monocyte functions. Int Arch Allergy Appl Immunol 1987;82:159-64.
8. Kimberly RP, Salmon JE, Bussel JB, Crow MK, Hilgartner MW. Modulation of mononuclear phagocyte functions by intravenous gamma globulin. J Immunol 1984;132:745-50.
9. Hashimoto F, Sakiyama Y, Matsumoto S. The suppressive effect of gamma globulin preparations on in vitro pokeweed mitogen-induced immunoglobulin production. Clin Exp Immunol 1986;65:409-15.
10. Antel J, Medof M, Oger J, Kuo H, Arnason B. Generation of suppressor cells by aggregated human globulin. Clin Exp Immunol 1981;43:351-6.
11. Kondo N, Ozawa T, Mushiake K, Motoyoshi F, Kameyama T, Kasahara K, et al. Suppression of immunoglobulin production of lymphocytes by intravenous immunoglobulin. J Clin Immunol 1991;11:152-8.
12. Stohl W. Cellular mechanisms in the in vitro inhibition of pokeweed mitogen induced B cell differentiation by immunoglobulin for intravenous use. J Immunol 1986;136:4407-13.
13. Heyman B. Fc-dependent IgG-mediated suppression of the antibody response: Fact or artefact? Scand J Immunol 1990;31:601-7.
14. Fridman WH. Regulation of B-cell activation and antigen presentation by Fc receptors [review]. Curr Opin Immunol 1993;5:355-60.
15. Phillips N, Parker D. Cross-linking of B lymphocyte Fcγ receptors and membrane immunoglobulin inhibits anti-immunoglobulin-induced blastogenesis. J Immunol 1984;132:627-32.
16. Phillips N, Gravel K, Tumas K, Parker D. IL-4 overcomes Fcγ receptor-mediated inhibition of mouse B lymphocyte proliferation without affecting inhibition of c-myc mRNA expression. J Immunol 1988;141:4243-9.
17. Chacko G, Tridandapani S, Damen J, Liu L, Krystal G, Coggeshall K. Negative signaling in B-lymphocytes induces tyrosine phosphorylation of the 145-kDa inositol polyphosphate 5-phosphatase, SHIP. J Immunol 1996;157:2234-8.
18. Diegel M, Rankin B, Bolen J, Dubois P, Kiener P. Cross-linking of Fcγ receptor to surface immunoglobulin on B-cells provides an inhibitory signal that closes the plasma membrane calcium channel. J Biol Chem 1994;269:11409-16.
19. Ashman R, Peckham D, Stunz L. Fc receptor off-signal in the B-cell involves apoptosis. J Immunol 1996;157:5-11.
20. White WB, Desbonnet CR, Ballow M, Immunoregulatory effects of intravenous immune serum globulin therapy in common variable hypogammaglobinemia. Am J Med 1987;83:431-6.
21. Leung DY, Burns JC, Newburger JW, Geha RS. Reversal of lymphocyte activation in vitro in the Kawasaki syndrome by intravenous gammaglobulin. J Clin Invest 1987;79:468-72.
22. Leung DYM, Kurt-Jones E, Newburger JW. Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet 1989;2:1298-302.
23. Shoenfeld Y. Idiotypic induction of autoimmunity: a new aspect of the idiotypic network. FASEB J 1994;8:1296-301.
24. Rossi F, Kazatchkine MD. Antiidiotypes against autoantibodies in pooled normal human polyspecific IgG. J Immunol 1989;143:4104-9.
25. Dietrich G, Kazatchkine MD. Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contains antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies. J Clin Invest 1990;85:620-5.
26. Sultan Y, Kazatchkine MD, Maisonneuve P. Anti-idiotypic suppression to autoantibodies to factor VIII by high-dose intravenous immunoglobulin. Lancet 1984;2:765-8.
27. Sultan Y, Rossi F, Kazatchkine MD. Recovery from anti-VIIIc (anti-hemophilic factor) autoimmune disease is dependent on generation of anti-idiotypes against anti-VIIIc autoantibodies. Proc Nat Acad Sci USA 1987;84:828-31.
28. Jeanette JC. Pathogenic potential of anti-neutrophil cytoplasmic autoantibodies. In: Gross WL, editor. ANCA-associated vasculitides: immunological and clinical aspects. New York: Plenum Press; 1993. p. 7-14.
29. Jayne DRW, Lockwood CM. Pooled intravenous immunoglobulin in the management of systemic vasculitis. Adv Exp Med Biol 1993;336:469-72.
30. Lockwood CM. New treatment strategies for systemic vasculitis: the role of intravenous immune globulin therapy. Clin Exp Immunol 1996;104(suppl 1):577-82.
31. Andersson JP, Andersson UG. Human intravenous immunoglobulin modulates monokine production in vitro. Immunology 1990;71: 372-6.
32. Shimozato T, Iwata M, Kawada H, T'amura N. Human immunoglobulin preparation for intravenous use induces elevation of cellular cyclic adenosine 3′:5′-monophosphate levels, resulting in suppression of tumour necrosis factor alpha and interleukin-1 production. Immunology 1991;72:497-501.
33. Amran D, Renz H, Lack G, Bradley K, Gelfand EW. Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin. Clin Immunol Immunopathol 1994;73:180-6.
34. Andersson J, Skansen-Saphir U, Sparrelid E, Andersson U. Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages. Clin Exp Immunol 1996;104(suppl 1):S10-S20.
35. Ruiz-de-Souza V, Carreno M, Kaveri S, Kazatchkine M. Selective induction of IL-1ra and IL-8 in human monocytes by normal polyspecific immunoglobulin G for therapeutic use. Eur J Immunol 1995;25:1267-73.
36. Aukrust P, Froland SS, Liabakk N-B, Muller F, Nordoy I, Haug C, et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994;84:2136-43.
37. Leung DYM. Kawasaki syndrome: immunomodulatory benefit and potential toxin neutralization by intravenous immune globulin. Clin Exp Immunol 1996;104:49-54.
38. Leung DY. The immunoregulatory effects of IVIG in Kawasaki disease and other autoimmune diseases. In: Ballow M, editor. IVIG therapy today. Totowa (NJ): Humana Press; 1992. p. 93-103.
39. Barnes P. Cytokines as mediators of chronic asthma. Am J Respir Crit Care Med 1994;150;S42-S49.
40. Mazer B, Gelfand E. An open-label study of high-dose intravenous immunoglobulin in severe childhood asthma. J Allergy Clin Immunol 1991;87:976-83.
41. Basta M, Kirshborn P, Frank MM, Fries LF. Mechanism of therapeutic effects of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest 1989;84:1974-81.
42. Basta M, Fries LF, Frank MM. High doses of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitized erythrocytes. Blood 1991;77:376-80.
43. Dalakas MC. Polymyositis, dermatomyositis, and inclusion-body myositis. N Engl J Med 1991;325:1487-98.
44. Dalakas MC, Illa I, D'Ambrosia JM, Soneidan SA, Stein DP, Otero C, et al. A controlled trial of high-dose immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329:1993-2000.
45. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994;94:1729-35.
46. Blasczyk R, Westhoff U, Grosse-Wilde H. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet 1993;341:789-90.
47. Kaveri S, Vassilev T, Hurez V, Lengagne R, Lefranc C, Cot S, et al. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest 1996;97: 865-9.
48. Lam L, Whitsett C, McNicholl J, Hodge T, Hooper J. Immunologically active proteins in intravenous immunoglobulin [letter]. Lancet 1993;342:678.
49. Swift AJ, Collins TS, Bugelski P, Winkelstein JA. Soluble human complement receptor type 1 inhibits complement-mediated host defense. Clin Diag Lab Immunol 1994;1:585-9.
50. Couser WG, Johnson RJ, Young BA, Yeh CG, Toth CA, Rudolph AR. The effects of soluble recombinant complement receptor 1 on complement-mediated experimental glomerulonephritis. J Am Soc Nephrol 1995;5:1888-94.
51. Vassilev T, Gelin C, Kaveri S, Zilber MT, Boumsell L, Kazatchkine MD. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg). Clin Exp Immunol 1993;92:369-72.
52. Hurez V, Kaveri SV, Mouhoub A, Dietrich G, Mani JC, Klatzmann D, et al. Anti-CD4 activity of normal human immunoglobulin G for therapeutic use (intravenous immunoglobulin, IVIg). Ther Immunol 1994;1:269-77.
53. Sullivan K. Immunomodulation in allogeneic marrow transplantation: use of intravenous immune globulin to suppress acute graftversus-host disease. Clin Exp Immunol 1996;104(suppl 1):S43-S48.
54. Sullivan K, Kopecky K, Jocom J. Immunomodulatory and anti-microbial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990;323:705-9.
55. Kotzin BL, Leung DY, Kappler J. Superantigens and human disease. Adv Immunol 1993;54:99-146.
56. Abe J, Kotzin BL, Jujo K. Selective expansion of T cells expressing T cell receptor variable regions Vβ2 and Vβ8 in Kawasaki disease. Proc Natl Acad Sci USA 1992;89:4066-70.
57. Abe J. Kotzin BL, Meissner C. Characterization of T cell repertoire changes in acute Kawasaki disease. J Exp Med 1993;177:791-6.
58. Takei S. Arora YK, Walker SM. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J Clin Invest 1993;91:602-7.
59. Saoudi A, Hurez V, De Kozak Y, Kuhn J, Kaveri SV, Kazatchkine MD, et al. Prevention of experimental autoimmune uveoretinitis by infusions of human therapeutic intravenous immunoglobulins in rats. Transplant Proc 1993;25:2838-9.
60. Rose N, Hill S. The pathogenesis of postinfectious myocarditis. Clin Immunol Immunopathol 1996;80:S92-S99.
61. Drucker NA, Colan SD, Lewis AB, Beiser AS, Wessel DL, Takahashi M, et al. γ-Globulin treatment of acute myocarditis in the pediatric population. Circulation 1993;89:252-7.
62. Acha-Orbea H, Mitchell DJ, Timmermann L, Wraith DC, Tausch GS, Waldor MK. et al. Limited heterogeneity of T cell receptors from T lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. Cell 1988;54:263-73.
63. Ben-Nun A, Wekerle H. Cohen IR. The rapid isolation of clonable antigen-specific T lymphocytes capable of mediating experimental autoimmune encephalomyelitis. Eur J Immunol 1981;11:195-9.
64. Achiron A, Margalit R, Hershkoviz R, Markovits D, Reshef T, Melamed E, et al. Intravenous immunoglobulin treatment of experimental T-cell mediated autoimmune disease. J Clin Invest 1994;93: 600-4.
65. Achiron A, Pras E, Gilad R, Ziv J, Mandel M, Gordon CR, et al. Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis. Arch Neurol 1992;49: 1233-6.
66. Achiron A, Barak Y, Goren M, Gabbay U, Miron S, Rotstein Z, et al. Intravenous immune globulin in multiple sclerosis: clinical and neuroradiological results and implications for possible mechanisms of action. Clin Exp Immunol 1996;104(suppl 1):S67-S70.
67. Buckley R, Schiff R. The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med 1991;325:110-7.
68. NIH Consensus Conference. Intravenous immunoglobulin: prevention and treatment of disease. JAMA 1990;264:3189-93.
69. Ratko T, Burnett D, Foulke G, Matuszewski K, Sacher R, the University Hospital Consortium Expert Panel for Off-label Use. Recommendations for off-label use of intravenously administered immunoglobulin preparations. JAMA 1995;273:1865-70.
70. Ballow M. Clinical implications of the mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. In: Morell A. Kazatchkine MD, editors. Intravenous immunoglobulin: research and therapy. Interlaken, Switzerland: Parthenon Publishing Group; 1997. p.123-7.